866-997-4948(US-Canada Toll Free)

Hepatitis D - Pipeline Review, H1 2015

Published By :

Global Markets Direct

Published Date : Apr 2015

Category :

Pharmaceutical

No. of Pages : 50


Global Markets Directs, Hepatitis D Pipeline Review, H1 2015, provides an overview of the Hepatitis Ds therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatitis D, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis D and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hepatitis D
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hepatitis D and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Hepatitis D products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hepatitis D pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hepatitis D
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hepatitis D pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Hepatitis D Overview 6
Therapeutics Development 7
Pipeline Products for Hepatitis D - Overview 7
Pipeline Products for Hepatitis D - Comparative Analysis 8
Hepatitis D - Therapeutics under Development by Companies 9
Hepatitis D - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Hepatitis D - Products under Development by Companies 12
Hepatitis D - Companies Involved in Therapeutics Development 13
Alnylam Pharmaceuticals, Inc. 13
BioDiem Ltd 14
Biogenomics Limited 15
Eiger BioPharmaceuticals, Inc. 16
Globeimmune, Inc. 17
Johnson & Johnson 18
REPLICor Inc. 19
SomaGenics Inc. 20
Hepatitis D - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
ALN-HDV - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
EBP-921 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
GI-18000 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
hepatitis D vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
interferon alfa-2b (recombinant) - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
lonafarnib - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Myrcludex-B - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
REP-9-AC' - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
RNAi Oligonucleotide for Hepatitis D - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
tipifarnib - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Hepatitis D - Recent Pipeline Updates 43
Hepatitis D - Product Development Milestones 46
Featured News & Press Releases 46
Apr 13, 2015: Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta at the European Association for the Study of the Liver Conference - April 22 to 26, 2015 46
Apr 10, 2015: Replicor to Present at the 2015 Lancet Viral Hepatitis Conference 46
Apr 02, 2015: Replicor Announces Completion of Enrollment in Phase II Trial 46
Feb 23, 2015: Eiger BioPharmaceuticals Announces Presentation of Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib 47
Dec 22, 2014: Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 47
Dec 22, 2014: Eiger Bio Receives Orphan Designation for Lonafarnib, a First In Class, Investigational Treatment for Hepatitis Delta Virus (HDV) Infection 48
Oct 01, 2014: REPLICor announces initiation of its Phase II clinical trial with REP 2139-Ca in combination with Pegasys in patients with hepatitis B / hepatitis D co-infection 48

Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

List of Table


Number of Products under Development for Hepatitis D, H1 2015 7
Number of Products under Development for Hepatitis D - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Hepatitis D - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 13
Hepatitis D - Pipeline by BioDiem Ltd, H1 2015 14
Hepatitis D - Pipeline by Biogenomics Limited, H1 2015 15
Hepatitis D - Pipeline by Eiger BioPharmaceuticals, Inc., H1 2015 16
Hepatitis D - Pipeline by Globeimmune, Inc., H1 2015 17
Hepatitis D - Pipeline by Johnson & Johnson, H1 2015 18
Hepatitis D - Pipeline by REPLICor Inc., H1 2015 19
Hepatitis D - Pipeline by SomaGenics Inc., H1 2015 20
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Stage and Target, H1 2015 23
Number of Products by Stage and Mechanism of Action, H1 2015 25
Number of Products by Stage and Route of Administration, H1 2015 27
Number of Products by Stage and Molecule Type, H1 2015 29
Hepatitis D Therapeutics - Recent Pipeline Updates, H1 2015 43

List of Chart


Number of Products under Development for Hepatitis D, H1 2015 7
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Early Stage Products, H1 2015 11
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Top 10 Targets, H1 2015 22
Number of Products by Stage and Top 10 Targets, H1 2015 23
Number of Products by Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 25
Number of Products by Top 10 Routes of Administration, H1 2015 26
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27
Number of Products by Top 10 Molecule Types, H1 2015 28
Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *